Technology evaluation: Matuzumab, Merck KGaA
Kim, T.
Current Opinion in Molecular Therapeutics 6(1): 96-103
2004
ISSN/ISBN: 1464-8431 PMID: 15011787 Document Number: 570240
Merck KGaA is developing matuzumab, a fully humanized epidermal growth factor receptor (EGFR)-specific monoclonal antibody, as a potential treatment for EGFR-bearing tumors. Matuzumab is currently undergoing phase II clinical trials for gastric, cervical, pancreatic and ovarian cancers.
Document emailed within 1 workday
Related Documents
Mikhaĭlitsyn, F.S.; Petrov, I.F.; Bol'shakova, A.I.; Lebedeva, M.N.; Lychko, N.D. 1995: The technology for manufacturing antiparasitic preparations. 4. the development of a technology for producing the anthelmintic bromoksan in finely dispersed form and the evaluation of its antifascioliasis activity Meditsinskaia Parazitologiia i Parazitarnye Bolezni 3: 41-42Mikhaĭlitsyn, F.S.; Drusviatskaia, S.K.; Uvarova, N.A.; Taits, S.Z.; Stoianovich, F.M.; Vol'kenshteĭn, I.B.; Lebedeva, M.N.; Krotov, A.I.; Lychko, N.D. 1994: The technology for manufacturing antiparasitic preparations. 3. the development of a technology for producing the anthelmintic embovin (pyrantel embonate) in finely dispersed form and the evaluation of its anthelmintic properties Meditsinskaia Parazitologiia i Parazitarnye Bolezni 2: 24-26
Calkin, A.C.; Thomas, M.C.; Cooper, M.E. 2003: MK-767. Kyorin/Banyu/Merck Current Opinion in Investigational Drugs 4(4): 444-448
Huckle, R. 2004: Gaboxadol. Lundbeck/Merck Current Opinion in Investigational Drugs 5(7): 766-773
Górowski, T.; Keydana-Jedrzejewska, B.; Zieliński, W. 1976: Clinical evalution of a synthetic thyroid preparation Novothyral-Merck Polski Tygodnik Lekarski 31(52): 2233-2234
Jørgensen, M.S.; Jørgensen, U. 2009: Green technology foresight of high technology: a social shaping of technology approach to the analysis of hopes and hypes Technology Analysis-Strategic Management 21(3): 363-379
Dolinský, A. 1982: Kinetics of plasma clearance of bromthalein [Merck] after hepatotropic contrast media Ceskoslovenska Radiologie 36(5): 316-320
Zetterström, R. 2007: Merck's oral rotavirus vaccine RotaTeq suspected to cause invagination in infants Lakartidningen 104(9): 646
Sakai, F.; Kondo, M.; Ito, H.; Ota, N. 1982: Evaluation of the extent of basic nursing technology knowledge at the end of the program at our school--self-evaluation by the students and a survey of frequencies of clinical training sessions Kango Tenbo. Japanese Journal of Nursing Science 7(3): 218-224
Zhang, Z. 2001: Technology evaluation: MG-98, MethylGene Current Opinion in Molecular Therapeutics 3(6): 599-604
Ding, C.; Jones, G. 2003: Technology evaluation: MRA, Chugai Current Opinion in Molecular Therapeutics 5(1): 64-69
Paul, S.ép. 2003: Technology evaluation: CpG-7909, Coley Current Opinion in Molecular Therapeutics 5(5): 553-559
Mukhtar, M.; Parveen, Z.; Pomerantz, R.J. 2000: Technology evaluation: PRO-542, Progenics Pharmaceuticals inc Current Opinion in Molecular Therapeutics 2(6): 697-702
Minev, B.R. 2003: Technology evaluation: HSPPC-96, antigenics Current Opinion in Molecular Therapeutics 5(6): 680-687
Errasti, F. 1996: Various sources of medical technology evaluation Revista de Medicina de la Universidad de Navarra 40(4): 4-5
Golab, J.; Stoklosa, T. 2005: Technology evaluation: SB-485232, GlaxoSmithKline Current Opinion in Molecular Therapeutics 7(1): 85-93
Gnanakumaran, G.; Babu, K.S. 2003: Technology evaluation: mepolizumab, GlaxoSmithKline Current Opinion in Molecular Therapeutics 5(3): 321-325
Galanis, E. 2002: Technology evaluation: Allovectin-7, Vical Current Opinion in Molecular Therapeutics 4(1): 80-87
Doehn, C.; Jocham, D. 2000: Technology evaluation: TG-1031, Transgene SA Current Opinion in Molecular Therapeutics 2(1): 106-111
Reinis, M. 2005: Technology evaluation: NV-1020, MediGene Current Opinion in Molecular Therapeutics 7(4): 366-375